<!DOCTYPE html>
<html lang="en" data-theme="light">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>5-Hydroxytryptamine (5-HT), Antagonists & Migraine - Essentials of Medical Pharmacology</title>
<link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap" rel="stylesheet">

<link rel="stylesheet" href="../styles/main.css">

<script>
MathJax = {
    tex: {
        inlineMath: [['$', '$'], ['\\(', '\\)']],
        displayMath: [['$$', '$$'], ['\\[', '\\]']],
        processEscapes: true,
        processEnvironments: true
    },
    svg: { fontCache: 'global' },
    options: {
        skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
    }
};
</script>
<script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
<a href="#main-content" class="skip-link">Skip to main content</a>

<button class="theme-toggle" id="theme-toggle" aria-label="Toggle dark mode">
    <span class="theme-toggle-icon light-icon">‚òÄÔ∏è</span>
    <span class="theme-toggle-icon dark-icon">üåô</span>
</button>

<div class="reading-progress-container">
    <div class="reading-progress-bar" id="reading-progress"></div>
</div>

<!-- Floating TOC -->
<nav class="floating-toc" id="floating-toc">
    <div class="floating-toc-header">
        <span>üìë</span> Table of Contents
    </div>
    <ul class="floating-toc-list">
        <li><a href="#introduction">5-Hydroxytryptamine (5-HT)</a></li>
        <li><a href="#synthesis">Synthesis & Destruction</a></li>
        <li><a href="#receptors">Serotonergic Receptors</a></li>
        <li><a href="#actions">Pharmacological Actions</a></li>
        <li><a href="#pathophysiology">Pathophysiological Roles</a></li>
        <li><a href="#drugs-affecting">Drugs Affecting 5-HT System</a></li>
        <li><a href="#antagonists">5-HT Antagonists</a></li>
        <li><a href="#ergot">Ergot Alkaloids</a></li>
        <li><a href="#migraine">Drug Therapy of Migraine</a></li>
        <li><a href="#case-study">Problem Directed Study</a></li>
    </ul>
</nav>

<div class="page-wrapper">
    <div class="container">
        <article class="document-article">
            <header class="document-header">
                <div class="header-badge">
                    <span>üß†</span>
                    <span>Topic 13</span>
                </div>
                <h1 class="document-title">5-Hydroxytryptamine, its Antagonists and Drug Therapy of Migraine</h1>
                <div class="title-meta">
                    <div class="meta-item">
                        <span>üìö</span>
                        <span>Autacoids and Related Drugs</span>
                    </div>
                    <div class="meta-item">
                        <span>‚è±Ô∏è</span>
                        <span>45 min read</span>
                    </div>
                </div>
            </header>

            <main id="main-content" class="content-wrapper">
                <!-- Section 1: Introduction -->
                <section class="content-section" id="introduction">
                    <div class="section-header">
                        <div class="section-number">01</div>
                        <h2 class="section-title">
                            <span class="title-icon">üß¨</span>
                            5-Hydroxytryptamine (Serotonin)
                        </h2>
                    </div>

                    <div class="content-card">
                        <p>Serotonin was the name given to the vasoconstrictor substance which appeared in the serum when blood clotted and Enteramine to the smooth muscle contracting substance present in enterochromaffin cells of gut mucosa. In the early 1950s both were shown to be 5-hydroxytryptamine (5-HT).</p>
                        <p>About 90% of body's content of 5-HT is localized in the enterochromaffin cells of stomach and intestines; most of the rest is in platelets and brain. It is also found in wasp and scorpion sting, and is widely distributed in invertebrates and plants (banana, pear, pineapple, tomato, stinging nettle, cowhage).</p>
                    </div>
                </section>

                <!-- Section 2: Synthesis -->
                <section class="content-section" id="synthesis">
                    <div class="section-header">
                        <div class="section-number">02</div>
                        <h2 class="section-title">
                            <span class="title-icon">‚öóÔ∏è</span>
                            Synthesis, Storage and Destruction
                        </h2>
                    </div>

                    <div class="content-card">
                        <p>5-HT is $\beta$-aminoethyl-5-hydroxyindole. It is synthesized from the amino acid tryptophan and degraded primarily by MAO and to a small extent by a dehydrogenase.</p>
                        
                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../../../../../assets/images/image-20251214-22d630be.jpeg" alt="Synthesis and degradation of 5-hydroxytryptamine" class="figure-image">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 12.1: Synthesis and degradation of 5-hydroxytryptamine (5-HT). MAO-Monoamine oxidase.</figcaption>
                        </figure>

                        <p>There is close parallelism between CAs and 5-HT. The decarboxylase is non-specific, acts on DOPA as well as 5-hydroxytryptophan (5-HTP) to produce DA and 5-HT respectively. Like NA, 5-HT is actively taken up by an amine pump serotonin transporter (SERT), a $\mathrm{Na}^{+}$ dependent carrier, which operates at the membrane of platelets (therefore, 5-HT does not circulate in free form in plasma) and serotonergic nerve endings. This pump is inhibited by selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs).</p>
                        <p>Platelets do not synthesize 5-HT but acquire it by uptake during passage through intestinal blood vessels. Again like CAs, 5-HT is stored within storage vesicles, and its uptake at the vesicular membrane by vesicular monoamine transporter (VMAT-2) is inhibited by reserpine, which causes depletion of CAs as well as 5-HT. The degrading enzyme MAO is also common for both. The isoenzyme MAO-A preferentially metabolizes 5-HT.</p>
                    </div>
                </section>

                <!-- Section 3: Receptors -->
                <section class="content-section" id="receptors">
                    <div class="section-header">
                        <div class="section-number">03</div>
                        <h2 class="section-title">
                            <span class="title-icon">üì°</span>
                            Serotonergic (5-HT) Receptors
                        </h2>
                    </div>

                    <div class="content-card">
                        <p>Four families of 5-HT receptors ($5\text{-HT}_1, 5\text{-HT}_2, 5\text{-HT}_3, 5\text{-HT}_{4-7}$) comprising of 14 receptor subtypes have so far been recognized. All 5-HT receptors (except $5\text{-HT}_3$) are G protein coupled receptors.</p>

                        <h3>Salient Features of Important 5-HT Receptor Subtypes</h3>
                        
                        <div class="table-responsive">
                            <table class="comparison-table">
                                <thead>
                                    <tr>
                                        <th>Subtype</th>
                                        <th>Mechanism</th>
                                        <th>Key Functions & Locations</th>
                                        <th>Selective Drugs</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td><strong>$5\text{-HT}_1$</strong></td>
                                        <td>Gi/Go ($cAMP \downarrow$, $K^+ \uparrow$, $Ca^{2+} \downarrow$)</td>
                                        <td>Autoreceptors; inhibit serotonergic activity.</td>
                                        <td></td>
                                    </tr>
                                    <tr>
                                        <td>$5\text{-HT}_{1A}$</td>
                                        <td></td>
                                        <td>Raphe nuclei, hippocampus.</td>
                                        <td>Agonist: <strong>Buspirone</strong> (Antianxiety)</td>
                                    </tr>
                                    <tr>
                                        <td>$5\text{-HT}_{1D/1B}$</td>
                                        <td></td>
                                        <td>Constricts cranial blood vessels, inhibits inflammatory neuropeptide release.</td>
                                        <td>Agonist: <strong>Sumatriptan</strong> (Antimigraine)</td>
                                    </tr>
                                    <tr>
                                        <td><strong>$5\text{-HT}_2$</strong></td>
                                        <td>Gq ($IP_3/DAG \uparrow$)</td>
                                        <td></td>
                                        <td></td>
                                    </tr>
                                    <tr>
                                        <td>$5\text{-HT}_{2A}$</td>
                                        <td></td>
                                        <td>Vascular/visceral smooth muscle contraction, platelet aggregation, neuronal activation.</td>
                                        <td>Antagonist: <strong>Ketanserin</strong></td>
                                    </tr>
                                    <tr>
                                        <td><strong>$5\text{-HT}_3$</strong></td>
                                        <td>Ligand gated cation channel</td>
                                        <td>Depolarizes neurones. Reflex effects: emesis, gut peristalsis, pain, itch. Area postrema (CTZ).</td>
                                        <td>Antagonist: <strong>Ondansetron</strong> (Antiemetic)</td>
                                    </tr>
                                    <tr>
                                        <td><strong>$5\text{-HT}_4$</strong></td>
                                        <td>Gs ($cAMP \uparrow$)</td>
                                        <td>Intestinal secretion, augmentation of peristalsis.</td>
                                        <td>Agonist: <strong>Cisapride</strong>, <strong>Renzapride</strong> (Prokinetic)</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                    </div>
                </section>

                <!-- Section 4: Actions -->
                <section class="content-section" id="actions">
                    <div class="section-header">
                        <div class="section-number">04</div>
                        <h2 class="section-title">
                            <span class="title-icon">‚öôÔ∏è</span>
                            Pharmacological Actions
                        </h2>
                    </div>

                    <div class="content-card">
                        <h4>1. CVS</h4>
                        <p>Arteries are constricted (direct action) as well as dilated (EDRF release). Larger arteries and veins are characteristically constricted. In microcirculation, 5-HT dilates arterioles and constricts venules $\rightarrow$ capillary pressure rises and fluid escapes. Isolated heart is stimulated. In intact animals, bradycardia is seen (coronary chemoreflex/Bezold Jarisch reflex). BP response is triphasic (early fall, brief rise, prolonged fall).</p>

                        <h4>2. Visceral smooth muscles</h4>
                        <p>Potent stimulator of g.i.t. (peristalsis increased, diarrhoea). Constricts bronchi (less potent than histamine). Action on other smooth muscles is feeble.</p>

                        <h4>3. Glands</h4>
                        <p>Inhibits gastric secretion (acid and pepsin) but increases mucus production (ulcer protective).</p>

                        <h4>4. Nerve endings</h4>
                        <p>Activates afferent nerve endings causing tingling, pricking sensation, pain. Depolarization of visceral afferents elicits reflexes, nausea and vomiting.</p>

                        <h4>5. Platelets</h4>
                        <p>Causes shape changes ($5\text{-HT}_{2A}$) and weak aggregation.</p>

                        <h4>6. CNS</h4>
                        <p>Poor blood-brain barrier penetration. Serves as a neurotransmitter (primarily inhibitory). Direct injection produces sleepiness, temperature changes, hunger.</p>
                    </div>
                </section>

                <!-- Section 5: Pathophysiology -->
                <section class="content-section" id="pathophysiology">
                    <div class="section-header">
                        <div class="section-number">05</div>
                        <h2 class="section-title">
                            <span class="title-icon">ü©∫</span>
                            Pathophysiological Roles
                        </h2>
                    </div>

                    <div class="content-card">
                        <ul class="enhanced-list">
                            <li class="list-item"><strong>Neurotransmitter:</strong> Involved in sleep, temperature regulation, cognitive function, behavior, mood, appetite, vomiting, pain. Implicated in anxiety, depression, aggression.</li>
                            <li class="list-item"><strong>Melatonin precursor:</strong> Regulates biological clock/circadian rhythm.</li>
                            <li class="list-item"><strong>Nausea and vomiting:</strong> Evoked by cytotoxic drugs/radiotherapy via $5\text{-HT}_3$ receptors in gut and brainstem.</li>
                            <li class="list-item"><strong>Migraine:</strong> Initiates vasoconstrictor phase, participates in neurogenic inflammation. Methysergide (prophylactic) and Sumatriptan (acute attack) are effective.</li>
                            <li class="list-item"><strong>Haemostasis:</strong> Accelerates platelet aggregation and clot formation; promotes vessel retraction.</li>
                            <li class="list-item"><strong>Raynaud's phenomenon:</strong> Triggered by 5-HT released from platelets.</li>
                            <li class="list-item"><strong>Hypertension:</strong> Increased responsiveness/reduced clearance in hypertensives.</li>
                            <li class="list-item"><strong>Carcinoid syndrome:</strong> Massive 5-HT production causes bowel hypermotility and bronchoconstriction.</li>
                        </ul>
                    </div>
                </section>

                <!-- Section 6: Drugs Affecting 5-HT -->
                <section class="content-section" id="drugs-affecting">
                    <div class="section-header">
                        <div class="section-number">06</div>
                        <h2 class="section-title">
                            <span class="title-icon">üíä</span>
                            Drugs Affecting 5-HT System
                        </h2>
                    </div>

                    <div class="content-card">
                        <ol class="enhanced-list">
                            <li class="list-item"><strong>Precursor:</strong> Tryptophan.</li>
                            <li class="list-item"><strong>Synthesis inhibitor:</strong> p-Chlorophenylalanine (PCPA) - inhibits tryptophan hydroxylase.</li>
                            <li class="list-item"><strong>Uptake inhibitor:</strong> TCAs, SSRIs (Fluoxetine) - antidepressant/antianxiety.</li>
                            <li class="list-item"><strong>Storage inhibitor:</strong> Reserpine, Fenfluramine (anorectic).</li>
                            <li class="list-item"><strong>Degradation inhibitor:</strong> MAO inhibitors.</li>
                            <li class="list-item"><strong>Neuronal degeneration:</strong> 5,6-dihydroxytryptamine.</li>
                            <li class="list-item"><strong>Receptor Agonists:</strong>
                                <ul>
                                    <li><strong>LSD:</strong> Nonselective agonist, potent hallucinogen.</li>
                                    <li><strong>Buspirone:</strong> $5\text{-HT}_{1A}$ partial agonist (Antianxiety).</li>
                                    <li><strong>Sumatriptan:</strong> $5\text{-HT}_{1D/1B}$ agonist (Antimigraine).</li>
                                    <li><strong>Cisapride:</strong> $5\text{-HT}_4$ agonist (Prokinetic).</li>
                                </ul>
                            </li>
                        </ol>
                    </div>
                </section>

                <!-- Section 7: Antagonists -->
                <section class="content-section" id="antagonists">
                    <div class="section-header">
                        <div class="section-number">07</div>
                        <h2 class="section-title">
                            <span class="title-icon">üõ°Ô∏è</span>
                            5-HT Antagonists
                        </h2>
                    </div>

                    <div class="content-card">
                        <h3>1. Cyproheptadine</h3>
                        <p>Primarily blocks $5\text{-HT}_{2A}$ receptors; also has H1 antihistaminic, anticholinergic and sedative properties. Increases appetite (used in poor eaters). Used in carcinoid syndrome, postgastrectomy dumping syndrome.</p>
                        
                        <h3>2. Methysergide</h3>
                        <p>Potent $5\text{-HT}_{2A/2C}$ antagonist. Chemically related to ergot alkaloids. Used for migraine prophylaxis and carcinoid, but went into disuse due to abdominal/pulmonary/endocardial fibrosis.</p>

                        <h3>3. Ketanserin</h3>
                        <p>Selective $5\text{-HT}_2$ blocker with negligible action on $5\text{-HT}_1$ or $5\text{-HT}_3$. Also blocks $\alpha_1$ adrenergic receptors (antihypertensive property).</p>

                        <h3>4. Clozapine</h3>
                        <p>Atypical antipsychotic; $5\text{-HT}_{2A/2C}$ blocker. Also blocks dopamine D4 receptors.</p>

                        <h3>5. Risperidone</h3>
                        <p>Combined $5\text{-HT}_{2A}$ + dopamine D2 antagonist. Atypical antipsychotic.</p>

                        <h3>6. Ondansetron</h3>
                        <p>Prototypical selective $5\text{-HT}_3$ antagonist. Remarkable efficacy in controlling nausea/vomiting following anticancer drugs and radiotherapy.</p>
                    </div>
                </section>

                <!-- Section 8: Ergot Alkaloids -->
                <section class="content-section" id="ergot">
                    <div class="section-header">
                        <div class="section-number">08</div>
                        <h2 class="section-title">
                            <span class="title-icon">üçÑ</span>
                            Ergot Alkaloids
                        </h2>
                    </div>

                    <div class="content-card">
                        <p>Ergot is a fungus <em>Claviceps purpurea</em> which grows on rye, millet and other grains. The grain is replaced by a purple, hard, curved body called 'sclerotium'. Epidemics of ergot poisoning (<strong class="term-definition" data-definition="Painful dry gangrene of hands and feet (due to vasospastic ischemia), miscarriages, hallucinations, and convulsions caused by ergot poisoning.">ergotism</strong>), due to consumption of contaminated grains, have been recorded from the beginning of history.</p>
                        <p>Ergot had been used by midwives to quicken labour since the middle ages. This use received medical sanction in the 19th century, but its dangers were recognized by the beginning of the 20th century and then it was advocated only after delivery. Dale and Barger (1906 onwards) isolated the ergot alkaloids and studied their pharmacology. Ergometrine was isolated in 1935.</p>
                        <p>Ergot contains a host of pharmacologically active substances-alkaloids, LSD, histamine, ACh, tyramine and other amines, sterols, etc.</p>

                        <h3>Natural Ergot Alkaloids</h3>
                        <p>These are tetracyclic indole containing compounds which may be considered as derivatives of lysergic acid. They are divided into:</p>
                        <ul class="enhanced-list">
                            <li class="list-item"><strong>Amine alkaloid:</strong> Ergometrine (Ergonovine): which is oxytocic.</li>
                            <li class="list-item"><strong>Amino acid alkaloids:</strong> Ergotamine, Ergotoxine (mixture of ergocristine + ergocornine + ergocryptine): they are vasoconstrictor and $\alpha$ adrenergic blocker/partial agonist.</li>
                        </ul>

                        <h3>Semisynthetic Derivatives</h3>
                        <ul class="enhanced-list">
                            <li class="list-item"><strong>Dihydroergotamine (DHE), Dihydroergotoxine (Codergocrine):</strong> are antiadrenergic, cerebroactive.</li>
                            <li class="list-item"><strong>2-Bromo-$\alpha$-ergocryptine (Bromocriptine):</strong> is a dopaminergic D2 agonist.</li>
                            <li class="list-item"><strong>Methysergide:</strong> it is mainly anti 5-HT.</li>
                        </ul>
                        <p>The ergot alkaloid related compounds have diverse pharmacological properties. They act as agonists, partial agonists and antagonists on certain subtypes of $\alpha$ adrenergic, serotonergic and dopaminergic receptors in a tissue specific manner.</p>

                        <h3>Actions</h3>
                        
                        <h4>Ergotamine</h4>
                        <p>It acts as a partial agonist and antagonist at $\alpha$ adrenergic and all subtypes of $5\text{-HT}_1$ and $5\text{-HT}_2$ receptors, but does not interact with $5\text{-HT}_3$ or dopamine receptors.</p>
                        <ul class="enhanced-list">
                            <li class="list-item"><strong>Vascular:</strong> Sustained vasoconstriction (because of very slow dissociation from the receptors), visceral smooth muscle contraction, vasomotor centre depression are produced, and the action of NA and 5-HT on smooth muscles is antagonized. However, the overall effect of oral/rectal doses of ergotamine on BP is insignificant.</li>
                            <li class="list-item"><strong>Chronic exposure (ergot poisoning):</strong> Vasoconstriction is accompanied by damage to capillary endothelium resulting in thrombosis, vascular stasis and gangrene.</li>
                            <li class="list-item"><strong>Other effects:</strong> It is a potent emetic (through CTZ and vomiting centre) and moderately potent oxytocic. At high doses CNS stimulation and paresthesias may be experienced.</li>
                        </ul>

                        <h4>Dihydroergotamine (DHE)</h4>
                        <p>Hydrogenation of ergotamine reduces serotonergic and $\alpha$-adrenergic agonistic actions, but enhances $\alpha$-receptor blocking property. Consequently DHE is a less potent vasoconstrictor; primarily constricts capacitance vessels and causes less intimal damage. It is a weaker emetic and oxytocic, but has some antidopaminergic action as well.</p>

                        <h4>Dihydroergotoxine (Codergocrine)</h4>
                        <p>This hydrogenated mixture of ergotoxine group of alkaloids is a more potent $\alpha$ blocker and a very weak vasoconstrictor. In the brain, a variety of partial agonistic/antagonistic actions on 5-HT receptors, as well as metabolic and vascular effects are produced. In addition, ACh release in cerebral cortex may be enhanced. Dihydroergotoxine has been advocated for treatment of dementia.</p>

                        <h4>Bromocriptine</h4>
                        <p>The 2-bromo derivative of ergocryptine is a relatively selective dopamine D2 agonist with prominent action on pituitary lactotropes (inhibits prolactin release), in striatum (antiparkinsonian) and in CTZ (emetic). The emetic action is weaker than that of ergotamine. In certain brain areas weak antidopaminergic action has also been shown. It has very weak anti 5-HT or $\alpha$ blocking actions and is not an oxytocic.</p>

                        <h4>Ergometrine (Ergonovine)</h4>
                        <p>This amine ergot alkaloid has very weak agonistic and practically no antagonistic action on $\alpha$ adrenergic receptors: vasoconstriction is not significant. Partial agonistic action on $5\text{-HT}_2$ receptors is most probably responsible for its powerful uterotonic effect. It is a moderately potent $5\text{-HT}_3$ antagonist in g.i. smooth muscle and a weak dopaminergic agonist on the pituitary lactotropes as well as CTZ; emetic potential is low. The most prominent action of ergometrine is contraction of myometrium, because of which it is used exclusively in obstetrics.</p>

                        <h3>Pharmacokinetics</h3>
                        <p>Oral bioavailability of amino acid ergot alkaloids and their hydrogenated derivatives is poor ($<1 \%$) due to slow and incomplete absorption as well as high first pass metabolism. Bioavailability is higher after sublingual and rectal administration, but still often erratic. They are metabolized in liver and excreted primarily in bile. Ergotamine is sequestrated in tissues-produces longer lasting actions compared to its plasma $t^{1/2}$ of 2 hours. Ergot alkaloids effectively cross blood brain barrier.</p>

                        <div class="callout callout--warning">
                            <div class="callout-header">
                                <span class="callout-icon">‚ö†Ô∏è</span>
                                <h4 class="callout-title">Adverse Effects & Contraindications</h4>
                            </div>
                            <div class="callout-content">
                                <p><strong>Adverse effects:</strong> Nausea, vomiting, abdominal pain, muscle cramps, weakness, paresthesias, coronary and other vascular spasm, chest pain (due to coronary vasoconstriction) are the frequent side effects.</p>
                                <p><strong>Contraindications:</strong> Sepsis, ischaemic heart disease, peripheral vascular disease, hypertension, pregnancy, liver and kidney disease.</p>
                            </div>
                        </div>

                        <h3>Preparations and Dose</h3>
                        <ul class="enhanced-list">
                            <li class="list-item"><strong>Ergotamine:</strong> For migraine 1-3 mg oral/sublingual, repeat as required (max 6 mg in a day); rarely 0.25-0.5 mg i.m. or s.c.; ERGOTAMINE 1 mg tab, 0.5 mg/ml inj.</li>
                            <li class="list-item"><strong>Dihydroergotamine:</strong> For migraine 2-6 mg oral (max 10 mg/day), 0.5-1 mg i.m., s.c. repeat hourly (max 3 mg); DIHYDERGOT, DHE 1 mg tab, MIGRANIL 1 mg/ml inj.</li>
                            <li class="list-item"><strong>Dihydroergotoxine (codergocrine):</strong> For dementia 1-1.5 mg oral or sublingual, 0.15-0.6 mg i.m., HYDERGINE 1.5 mg tab, CERELOID 1 mg tab.</li>
                        </ul>
                    </div>
                </section>

                <!-- Section 9: Migraine -->
                <section class="content-section" id="migraine">
                    <div class="section-header">
                        <div class="section-number">09</div>
                        <h2 class="section-title">
                            <span class="title-icon">ü§ï</span>
                            Drug Therapy of Migraine
                        </h2>
                    </div>

                    <div class="content-card">
                        <p>Migraine is a mysterious disorder characterized by pulsating headache, usually restricted to one side, which comes in attacks lasting 4-48 hours and is often associated with nausea, vomiting, sensitivity to light and sound, flashes of light, vertigo, loose motions and other symptoms.</p>
                        
                        <div class="grid grid-2">
                            <div class="grid-item">
                                <h4>Migraine with aura</h4>
                                <p>(Classical migraine) Headache is preceded by visual or other neurological symptoms.</p>
                            </div>
                            <div class="grid-item">
                                <h4>Migraine without aura</h4>
                                <p>(Common migraine) Pulsatile dilatation of certain large cranial vessels is the immediate cause of pain.</p>
                            </div>
                        </div>

                        <h3>Pathogenesis</h3>
                        <ul class="enhanced-list">
                            <li class="list-item"><strong>Vascular theory:</strong> Initial vasoconstriction or shunting of blood through carotid arterio-venous anastomoses produces cerebral ischaemia and starts the attack.</li>
                            <li class="list-item"><strong>Neurogenic theory:</strong> Spreading depression of cortical electrical activity followed by vascular phenomena. Some triggering event produces neurogenic inflammation of the affected blood vessel wall which is amplified by retrograde transmission in the afferent nerves and release of mediators like 5-HT, neurokinin, substance P, calcitonin gene related peptide (CGRP), nitric oxide, etc. Perivascular edema occurs due to leakage of plasma from the inflamed cranial vessels, and pain nerve endings in the dura are activated by stretching.</li>
                        </ul>
                        <p>Changes in blood/urinary levels of 5-HT and its metabolites during migraine attack, its precipitation by 5-HT releasers and efficacy of drugs having actions in the serotonergic system to prevent/abort/terminate migraine attacks suggests a pivotal role of 5-HT in this disorder.</p>

                        <h3>Therapeutic Strategy</h3>
                        <div class="table-responsive">
                            <table class="comparison-table">
                                <thead>
                                    <tr>
                                        <th>Severity</th>
                                        <th>Drug therapy</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td><strong>Mild</strong></td>
                                        <td>Simple analgesics/NSAIDs or their combinations ($\pm$ antiemetic)</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Moderate</strong></td>
                                        <td>NSAIDs combinations/a triptan/ ergot alkaloids (+ antiemetic)</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Severe</strong></td>
                                        <td>a Triptan/ergot alkaloids (+ antiemetic)<br>
                                        <strong>+ Prophylaxis:</strong><br>
                                        - Propranolol/other $\beta$ blockers<br>
                                        - Amitriptyline/other tricyclic antidepressants<br>
                                        - Flunarizine/other $\mathrm{Ca}^{2+}$ channel blockers<br>
                                        - Valproate/topiramate</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <h3>Specific Antimigraine Drugs</h3>

                        <h4>1. Ergot Alkaloids</h4>
                        <p><strong>Ergotamine:</strong> It is the most effective ergot alkaloid for migraine. Given early in attack, lower doses generally suffice, and relief is often dramatic. Oral/sublingual route is preferred. Parenteral administration, though rapid in action is more hazardous.</p>
                        <p><em>Mechanism:</em> Constricts the dilated cranial vessels and/or specific constriction of carotid A-V shunt channels. Also reduces neurogenic inflammation and leakage of plasma in duramater. Actions mediated through partial agonism at $5\text{-HT}_{1D/1B}$ receptors.</p>
                        <p><strong>Dihydroergotamine (DHE):</strong> Nearly as effective as ergotamine and preferred for parenteral administration because injected DHE is less hazardous.</p>
                        <p><strong>Current status:</strong> Rarely used now due to erratic oral absorption and frequent side effects (nausea, vomiting, muscle cramps). Used when triptans fail or for cost considerations. No prophylactic value.</p>
                        <p><strong>Combinations:</strong> Caffeine 100 mg taken with ergotamine enhances absorption and adds vasoconstricting action. MIGRIL (Ergotamine 2 mg + caffeine 100 mg + cyclizine 50 mg).</p>

                        <h4>2. Selective 5-HT$_{1D/1B}$ Agonists (Triptans)</h4>
                        <p>This novel class of antimigraine drugs selectively activate $5\text{-HT}_{1D/1B}$ receptors. Currently, they are the first line drugs for patients who fail to respond to analgesics.</p>

                        <div class="callout callout--info">
                            <div class="callout-header">
                                <span class="callout-icon">üí°</span>
                                <h4 class="callout-title">Mechanism of Action</h4>
                            </div>
                            <div class="callout-content">
                                <p>Antimigraine activity is ascribed to $5\text{-HT}_{1D/1B}$ receptor mediated constriction of dilated cranial blood vessels, especially the arterio-venous shunts. They also inhibit inflammatory neuropeptide release and suppress neurogenic inflammation.</p>
                            </div>
                        </div>

                        <p><strong>Sumatriptan:</strong> The prototype. Administered at the onset of an attack, it is as effective and better tolerated than ergotamine. About 3/4 patients obtain complete/significant relief within 2-3 hours. Recurrence within 24 hr occurs in 20-40% patients (short $t^{1/2}$). Suppresses nausea/vomiting.</p>
                        <ul class="enhanced-list">
                            <li class="list-item"><strong>Pharmacokinetics:</strong> Rapid absorption after s.c. injection. Oral bioavailability low (~15%). Metabolized by MAO-A.</li>
                            <li class="list-item"><strong>Side effects:</strong> Tightness in head/chest, heat, paresthesias, dizziness (short lasting). Serious: coronary vasospasm, MI risk.</li>
                            <li class="list-item"><strong>Contraindications:</strong> Ischaemic heart disease, hypertension, epilepsy, hepatic/renal impairment, pregnancy. Do not combine with ergotamine within 24 hrs.</li>
                            <li class="list-item"><strong>Dose:</strong> 50-100 mg oral; 6 mg s.c. (rapid action); 25 mg nasal spray.</li>
                        </ul>

                        <p><strong>Other Triptans:</strong></p>
                        <div class="table-responsive">
                            <table class="comparison-table">
                                <thead>
                                    <tr>
                                        <th>Drug</th>
                                        <th>Oral Bioavailability</th>
                                        <th>$T_{max}$ (hr)</th>
                                        <th>$t^{1/2}$ (hr)</th>
                                        <th>Oral Dose (mg)</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td><strong>Sumatriptan</strong></td>
                                        <td>15%</td>
                                        <td>1.5-2</td>
                                        <td>~2</td>
                                        <td>50-100</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Rizatriptan</strong></td>
                                        <td>45%</td>
                                        <td>1-1.5</td>
                                        <td>2-3</td>
                                        <td>5-10</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Naratriptan</strong></td>
                                        <td>70%</td>
                                        <td>2-3</td>
                                        <td>6</td>
                                        <td>2.5</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Zolmitriptan</strong></td>
                                        <td>40%</td>
                                        <td>1.5-2</td>
                                        <td>2-3</td>
                                        <td>2.5</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Frovatriptan</strong></td>
                                        <td>25%</td>
                                        <td>2-4</td>
                                        <td>26</td>
                                        <td>2.5</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <h3>Prophylaxis of Migraine</h3>
                        <p>Recommended for moderate-to-severe migraine when 2-3 or more attacks occur per month. None is effective in all cases.</p>
                        <ol class="enhanced-list">
                            <li class="list-item"><strong>$\beta$-Adrenergic blockers:</strong> Propranolol is the most commonly used. Reduces frequency/severity in 70% patients. Start 40 mg BD.</li>
                            <li class="list-item"><strong>Tricyclic antidepressants:</strong> Amitriptyline (25-50 mg at bed time). Effective independent of antidepressant property.</li>
                            <li class="list-item"><strong>Calcium channel blockers:</strong> Flunarizine (10-20 mg OD) is a weak $\mathrm{Ca}^{2+}$ blocker that inhibits $\mathrm{Na}^{+}$ channels as well. Verapamil is less effective.</li>
                            <li class="list-item"><strong>Anticonvulsants:</strong> Valproic acid (400-1200 mg/day), Gabapentin, Topiramate. Indicated when refractory to other drugs.</li>
                            <li class="list-item"><strong>CGRP antagonist:</strong> Erenumab (monoclonal antibody) injected s.c. once a month for severe migraine.</li>
                            <li class="list-item"><strong>5-HT antagonists:</strong> Methysergide and cyproheptadine (prophylactic effect less impressive, not used now).</li>
                        </ol>
                    </div>
                </section>

                <!-- Section 10: Case Study -->
                <section class="content-section" id="case-study">
                    <div class="section-header">
                        <div class="section-number">10</div>
                        <h2 class="section-title">
                            <span class="title-icon">ü§î</span>
                            Problem Directed Study
                        </h2>
                    </div>

                    <div class="content-card">
                        <div class="callout callout--note">
                            <div class="callout-header">
                                <span class="callout-icon">üìù</span>
                                <h4 class="callout-title">Case 12.1</h4>
                            </div>
                            <div class="callout-content">
                                <p>A 36 years lady presents with the complaint of episodes of unilateral pulsatile headache for the past 2 years... severity and frequency has progressively increased... recurring nearly every 1-2 weeks... accompanied by blurred vision, flashes of light... vomiting. Not relieved by over-the-counter analgesics.</p>
                                <p><strong>(a) Medication for headache episodes:</strong> Since OTC analgesics are failing and attacks are severe with vomiting, a specific antimigraine drug like <strong>Sumatriptan</strong> (50-100 mg oral) or <strong>Rizatriptan</strong> (10 mg) should be prescribed at the onset of attack. Due to vomiting, <strong>Sumatriptan 25 mg nasal spray</strong> or 6 mg s.c. injection would be more effective. An antiemetic like <strong>Metoclopramide</strong> (10 mg) should be taken first to aid absorption of oral drugs and control vomiting.</p>
                                <p><strong>(b) History/Examination:</strong> Rule out ischaemic heart disease, hypertension, and pregnancy (contraindications for triptans/ergot). Check BP and history of chest pain.</p>
                                <p><strong>(c) Prophylaxis:</strong> Since frequency is 1-2 weeks (2-4 per month) and incapacitating, prophylaxis is indicated. <strong>Propranolol</strong> (40 mg BD) or <strong>Flunarizine</strong> (10 mg OD) can be started.</p>
                            </div>
                        </div>
                    </div>
                </section>

            </main>

            <nav class="document-nav">
                <div class="nav-container">
                    <a href="topic-12-histamine.html" class="nav-button nav-button--large nav-button--previous">
                        <div class="nav-label">Previous</div>
                        <div class="nav-title">Histamine & Antihistaminics</div>
                    </a>
                    
                    <div class="document-progress">
                        <div class="progress-indicator">
                            <span>13</span>
                            <span class="progress-separator">/</span>
                            <span>13</span>
                        </div>
                        <div class="progress-bar-container">
                            <div class="progress-bar-fill" style="width: 100%;"></div>
                        </div>
                        <div class="progress-label">Topic Progress</div>
                    </div>
                    
                    <a href="topic-14-prostaglandins.html" class="nav-button nav-button--large nav-button--next">
                        <div class="nav-label">Back to</div>
                        <div class="nav-title">Prostaglandins, Leukotrienes (Eicosanoids) and Platelet Activating Factor</div>
                    </a>
                </div>
            </nav>
        </article>
    </div>
</div>

<script src="../js/theme.js"></script>
<script src="../js/navigation.js"></script>
<script src="../js/interactions.js"></script>
</body>
</html>